Meta-analysis: Risk of fractures with acid-suppressing medication

Bone

Volumn 48, Issue 4, 2011, Pages 768-776

  Kwok, Chun Shing ^a   Yeong, Jessica Ka Yan ^a   Loke, Yoon Kong ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Fractures; Histamine 2 receptor antagonists; Meta analysis; Proton pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ARTICLE; DRUG EXPOSURE; FRACTURE; HIP FRACTURE; HUMAN; META ANALYSIS (TOPIC); RISK ASSESSMENT; RISK FACTOR; SPINE FRACTURE; SYSTEMATIC REVIEW;

FRACTURES, BONE; HISTAMINE H2 ANTAGONISTS; HUMANS; ODDS RATIO; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 79952704502     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.12.015     Document Type: Article

References (40)

1. Yang Y.-X., Lewis J.D., Epstein S., Metz D.C. Long term proton pump inhibitor therapy and risk of hip fractures. JAMA 2006, 296(24):2947-2953.
2. Corley D.A., Kubo A., Zhao W., Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010, 139(1):93-101.
3. Vestegaard P., Rejnmakr L., Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists and other antacid medication and risk of fracture. Calcif Tissue Int 2006, 79:76-83.
4. Gray S.L., LaCroix A.Z., Larson J., Robbins J., Cauley J.A., Manson J.E., et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Intern Med 2010, 170(9):765-771.
5. Yu E.W., Blackwell T., Ensrud K.E., Hillier T.A., Lane L.E., Orwoll E., et al. Acid-suppressive medication and risk of bone loss and fractures in older adults. Calcif Tissue Int 2008, 83:251-259.
6. Kaye J.A., Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008, 28(8):951-959.
7. Roux C., Briot K., Gossec L., Kolta S., Blenk T., Felsenberg D., et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009, 84:13-19.
8. de Vries F., Cooper A.L., Cockle S.M., van Staa T.P., Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphophonates. Osteoporos Int 2009, 20(12):1989-1998.
9. Grisso J.A., Kelsey J.L., O'Brien L.A., Miles C.G., Sidney S., Maislin G., et al. Risk factors for hip fractures in men. Am J Epidemiol 1997, 145(9):786-793.
10. US Food and Drug Administration FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors, 25 May 2010 Accessed 9 September 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm.
11. Heidelbaugh J.J., Goldberg K.L., Inadomi J.M. Adverse risk associated with proton pump inhibitors: a systematic review. Gastroenterol Hepatol 2009, 5(10):725-734.
12. Loke Y.K., Price D., Herxheimer A. Chapter 14: Adverse effects. Cochrane Handbook for Systematic Reviews of Interventions 2008, John Wiley & Sons, Chichester (UK. J.P.T. Higgins, S. Green (Eds.).
13. Davies H.T., Crombie I.K., Tavakoli M. When can odds ratios mislead?. BMJ 1998, 316(7136):989-991.
14. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
15. Bucher H.C., Guyatt G.H., Griffith L.E., Walter S.D. The results of direct and indirect treatment comparison in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691.
16. Well G.A., Sultan S.A., Chen L., Khan M., Coyle D. Indirect treatment comparison [computer program] 1.0 edn 2010, Canadian Agency for Drugs and Technologies in Health, Ottawa, Available at:, (accessed 3 February 2010). http://www.cadth.ca/index.php/en/itc-user-guide.
17. Targownik L.E., Lix L.M., Metge C.J., Prior H.J., Leung S., Leslie W.D. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008, 179(4):319-326.
18. Pouwels S., Lalmohamed A., Souverein P., Cooper C., Veldt B.J., Leufkens, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int Jun 29 2010, [Electronic publication ahead of print].
19. Bonds D.E., Larson J.C., Schwartz A.V., Strotmeyer E.S., Robbins J., Rodriguez B.L., et al. J Clin Endocrinol Metab 2006, 91(9):3404-3410.
20. O'Connell M.B., Madden D.M., Murray A.M., Heaney R.P., Kerzner L.J. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005, 118:778-781.
21. Graziani G., Badalamenti S., Como G., Gallieni M., Finazzi S., Angelini C., et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 2002, 91:474-479.
22. Graziani G., Como G., Badalamentti S., Finazzi S., Malesci A., Gallieni M., et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995, 10:1376-1380.
23. Knox T.A., Kassarjian Z., Dawson-Hughes B., Golner B.B., Dallal G.E., Arora S., et al. Calcium absorption in elderly subjects on high- and low-fiber diets: effect of gastric acidity. Am J Clin Nutr 1991, 53:1480-1486.
24. Recker R.R. Calcium absorption and achlorohydria. N Engl J Med 1985, 313:70-73.
25. Serfaty-Lacrosniere C., Wood R.J., Voytko D., Saltzman J.R., Pedrosa M., Sepe T.E., et al. Hypochlorohydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995, 14:364-368.
26. Sheikh M.S., Santa Ana C.A., Nicar M.J., Schiller L.F., Fordtran J.S. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987, 317:532-536.
27. Yang Y.X. Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf 2008, 2:204-209.
28. Gagnemo-Persson R., Samuelsson A., Hakanson R., Persson P. Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol and restricted food intake. Calcif Tissue Int 1997, 61(3):210-215.
29. Grimelius L., Johnsson H., Lundqvist G., Olazabal A., Polak J.H., Pearse G.E. The parathyroid glands in experimentally induced hypergastinemia in the rat. Scand J Gastroenterol 1977, 12:739-744.
30. Farina C., Gagliardi S. Selective inhibition of osteoclast vacuolar H+ATPase. Curr Pharm Des 2002, 8:2033-2048.
31. Sahara T., Itoh K., Debari K., Saski T. Specific biological function of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts. Anat Rec Discov Mol Evol Biol 2003, 270(2):152-161.
32. Saski T. Recent advances in the ultrastructural assessment of osteoclastic resorptive functions. Microsc Res Tech 1996, 33:182-191.
33. Shibata T., Amano H., Yamada S., Ohya K. Mechanism of proton transport in isolated rat osteoclasts attached to bone. J Med Dent Sci 2000, 47(3):177-185.
34. Mattsson J.P., Vaananen K., Wallmark B., Lorentzon P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta 1991, 1065:261-268.
35. Mizunashi K., Furukawa Y., Katano K., Abe K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993, 53:21-25.
36. Tuukkanen J., Koivukangas A., Jamasa T., Sundquist K., Mackay C.A., Marks S.C. Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations. J Bone Miner Res 2000, 15:1905-1911.
37. Rumenapf G., Schwille P.O., Erben R.G., Schreiber M., Berge B., Fries W., et al. Gastric fundectomy in the rat: effects on mineral and bone metabolism, with emphasis on the gastric-calcitonin-parathyroid hormone-vitamin D axis. Calcif Tissue Int 1998, 63(5):433-441.
38. Gepp H., Koch M., Scwille P.O., Erben R.G., Rumeaphf G., Schmiedl A., et al. Vagus-sparing gastric fundectomy in the rat: development of osteopenia, relationship to urinary phosphate and net acid excretion, serum gastric and vitamin D. Res Exp Med (Berl) 2000, 200:1-16.
39. Targownik L.E., Lix L.M., Leung S., Leslie W.D. Proton-pump inhibitors use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010, 138:896-904.
40. Ioannidis J.P., Trikalinos T.A. The appropriateness of asymmetry test for publication bias in meta-analyses: a large survey. CMAJ 2007, 176:1091-1096.